New EU Project to Develop a Novel Pandemic Influenza Vaccine

EUInternational experts in the field of human virus research and vaccine development have teamed up to develop a pandemic influenza vaccine. The aim of the EU-funded FluVac project is to conduct research and development (R&D) into a novel pandemic influenza vaccine that could be used as a potential emergency vaccination. The project partners, recently awarded a grant of €3.5 million under the EU's Sixth Framework Programme (FP6), plan to deliver a prototype vaccine within four years.

The emergence of the highly pathogenic strain of avian flu (H5N1) in South East Asia was accompanied by concerns about a potential pandemic influenza outbreak. Prevention and control in such a scenario would depend on the availability of large quantities of a highly effective vaccine at short notice.

"In the event of an influenza pandemic, vaccination will play a key role in its control. Therefore, availability of a sufficient number of vaccine doses will be critical. In this project, we will exploit the potency of the adjuvant [a substance added to a vaccine to increase the body's immune response to it] to potentiate immunity and to reduce the antigen dose required per vaccination," explains Dr Luuk Hilgers, the scientific coordinator of the project at Nobilon International.

As combining a powerful new adjuvant with a novel H5N1 vaccine has produced encouraging results, the project will now move on to developing the vaccine in phase I and II clinical trials. These are expected to take place within two years.

If the trials are successful, the consortium will then carry out further clinical development, and eventually market the vaccine.

"At the end of the project, we expect to have a prototype (concept) flu vaccine with proven efficacy and safety in humans, ready for further development to control an influenza pandemic," Dr Hilgers explained.

The European Commission has funded many research projects targeting influenza, providing funding of over €90 million since 2001. Such research will continue under FP7, and the Commission recently announced the first projects in this area that will receive funding under FP7. Of 44 influenza-related proposals received by the Commission, 11 have been pre-selected for funding. The projects selected are set to receive some €27 million between them, and address issues such as diagnostics, drug and vaccine development and capacity building.

For further information, please visit:
http://ec.europa.eu/food/animal/diseases/controlmeasures/avian/index_en.htm

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...